(Total Views: 699)
Posted On: 09/11/2025 8:10:41 AM
Post# of 156908
Kat -- look @ this with Mr. Hoffman
From his past 2023 Kintara Therapeutics:
*"We are honored to participate in the Glioblastoma (GBM) Awareness Day and to be joined by patients, advocates, physicians, and politicians to continue to raise awareness for GBM research and advancement,"
* Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) is an international, innovative platform study designed to more rapidly identify and confirm effective therapies for patients with glioblastoma through response adaptive randomization and a seamless Phase 2/3 design.
The study, conceived by over 130 key opinion leaders, is conducted under a master protocol, allowing multiple therapies or combinations of therapies from different pharmaceutical partners to be evaluated simultaneously."
https://www.prnewswire.com/news-releases/kint...80592.html
____
His Kintara Glioblastoma drug was in this study & is the reference he just spoke of yesterday.
130 KOL's --- Mr. Hoffman has the ear of serious GBM heavy-hitters. No surprise he announced funding for our Alzheimer’s study.
Dr. J said in his video KOL's determined to validate the site of impact from the ICI on Glio. Is it peripheral or brain. So sounds like Mr. Hoffman had already brought his KOL connections to Leronlimab.
____
& yes he did leave Kintara 2 yrs ago, but of course you don't just "walk away" from deep rooted connections like that.
Case in point --- he even switched us to his IR choice..... Russo Partners. Kintara & now bottom of our WCH press releases/Contact --- Russo.
Mr. Hoffman had zero stress in his demeanor about funding(s).
Connected through a really good demeanor about his career & Leronlimab. Of course topped with validating best results are LL before ICI & will be working WITH, the ICI's to get the combo world-wide
Alot of phenomenal pieces here....&...there, right there...over here, etc, etc., but coming together !!
From his past 2023 Kintara Therapeutics:
*"We are honored to participate in the Glioblastoma (GBM) Awareness Day and to be joined by patients, advocates, physicians, and politicians to continue to raise awareness for GBM research and advancement,"
* Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) is an international, innovative platform study designed to more rapidly identify and confirm effective therapies for patients with glioblastoma through response adaptive randomization and a seamless Phase 2/3 design.
The study, conceived by over 130 key opinion leaders, is conducted under a master protocol, allowing multiple therapies or combinations of therapies from different pharmaceutical partners to be evaluated simultaneously."
https://www.prnewswire.com/news-releases/kint...80592.html
____
His Kintara Glioblastoma drug was in this study & is the reference he just spoke of yesterday.
130 KOL's --- Mr. Hoffman has the ear of serious GBM heavy-hitters. No surprise he announced funding for our Alzheimer’s study.
Dr. J said in his video KOL's determined to validate the site of impact from the ICI on Glio. Is it peripheral or brain. So sounds like Mr. Hoffman had already brought his KOL connections to Leronlimab.
____
& yes he did leave Kintara 2 yrs ago, but of course you don't just "walk away" from deep rooted connections like that.
Case in point --- he even switched us to his IR choice..... Russo Partners. Kintara & now bottom of our WCH press releases/Contact --- Russo.
Mr. Hoffman had zero stress in his demeanor about funding(s).
Connected through a really good demeanor about his career & Leronlimab. Of course topped with validating best results are LL before ICI & will be working WITH, the ICI's to get the combo world-wide
Alot of phenomenal pieces here....&...there, right there...over here, etc, etc., but coming together !!
(8)
(0)
